Table 1.

CMV Disease incidence in the preemptive era. Incidence of CMV disease in the placebo groups in randomized trials.

Drug	Study	N∘ Patients	CMV disease incidence
Maribavir	Marty FM, Lancet ID 2011 (4)	227	2.4% (at 6 months)
Brincidofovir	Marty FM. NEJM 2013 (5)	59	3.0% (at 3 months)
Letermovir	Chemaly RF. NEJM 2014 (6)	33	0% (at 3 months)
Valganciclovir	Boeckh M, Ann I. Med. 2015 (7)	89	2.0% (at 9 months)